REX Shares launched the REX Peptide ETF (PEPT), offering exposure to companies developing, manufacturing, delivering and commercializing peptide-based products. The fund will be listed on Nasdaq with an expense ratio of 0.65%. It is REX’s third thematic ETF.
PEPT is based on the VettaFi Peptide Index, covering medicines, manufacturing and medical devices, supplements and skincare. As of September 30, 2026, the index had 36 constituents, with 52.9% of its weight in U.S. companies and 47.1% in non-U.S. companies. At least 80% of index weight goes to companies deriving at least half their revenue or research and development activity from peptides, with caps on individual constituents.
The fund has no operating history, and the index launched September 24, 2026. Exposure to peptides may be indirect.